FDA Greenlights Generics for Flu Drug FLUMADINE Without Interruptions
Published Date: 4/9/2025
Notice
Summary
The FDA checked and confirmed that FLUMADINE 100 mg tablets weren’t taken off the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they follow the rules. People who rely on this flu medicine can keep counting on it without any interruptions or extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generic Approvals Can Continue
The FDA determined that FLUMADINE (rimantadine hydrochloride) tablet, 100 milligrams, was not withdrawn from sale for reasons of safety or effectiveness. Because of that determination, the FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this product and will allow ANDAs that refer to the product to continue being approved if they meet legal and regulatory requirements.
Patient Access Preserved
If you rely on FLUMADINE (rimantadine hydrochloride) tablet, 100 milligrams, the FDA confirmed it was not withdrawn for safety or effectiveness. That means FDA will allow generic approvals to continue, so people who use this flu medicine can expect continued availability without interruption as long as manufacturers meet approval rules.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-06049, Growing, Harvesting, Processing, and Distribution of Poppy Seeds-Industry Practices Related to Opiate Alkaloids; Request for Information; Extension of Comment Period
The FDA is giving more time for people to share info about how poppy seeds are grown, harvested, processed, and sold, especially how to keep opiate chemicals low. This affects farmers, processors, and sellers who want to help keep poppy seed products safe to eat. The extra comment time means everyone can have their say before any new rules or changes happen.
Next: 2025-06051, Electronic Study Data Submission; Data Standards; Clinical Data Interchange Standards Consortium Dataset-JavaScript Object Notation; Request for Comments
The FDA wants to hear from drug and biologics makers about using a new, modern data format called Dataset-JSON to send study data. This could replace the old SAS XPT format, making data sharing faster and easier. If adopted, companies might need to update their systems, but it could save time and improve how data is reviewed—so get ready to share your thoughts soon!